Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues

International Immunology

Volumn 11, Issue 12, 1999, Pages 1971-1979

  Valmori, Danila ^b   Fonteneau, Jean Francois ^a   Valitutti, Salvatore ^b   Gervois, Nadine ^a   Dunbar, Rod ^c   Liénard, Danielle ^b   Rimoldi, Donata ^b   Cerundolo, Vincenzo ^c   Jotereau, Francine ^a   Cerottini, Jean Charles ^b   Speiser, Daniel E ^b   Romero, Pedro ^b  

^a INSERM   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic T lymphocyte; Cytotoxicity; T lymphocytes; Tumor immunity; Vaccination

Indexed keywords

CALCIUM ION; CD8 ANTIGEN; CYTOKINE; HLA A2 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPH NODE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE;

EID: 0033455555     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/11.12.1971     Document Type: Article

References (39)

1. Robbins, P. F. and Kawakami, Y. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
2. Boon, T., Coulie, P. and Van den Eynde, B. 1997. Tumor antigens recognized by T cells, Immunol. Today 18:267.
3. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E. and Rosenberg, S. A. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
4. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T. and Rosenberg, S. A. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91:3515.
5. Coulie, P. G., Brichard, V., Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., Renauld, J. C. and Boon, T. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
6. Spagnoli, G. C., Schaefer, C., Willimann, T. E., Kocher, T., Amoroso, A., Juretic, A., Zuber, M., Luscher, U., Harder, F. and Heberer, M. 1995. Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes a study in an unselected group of HLA-A2.1 positive patients. Int. J. Cancer 64:309.
7. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E. and Rosenberg, S. A. 1995. Induction of tumorreactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
8. +melanoma patients have a memory phenotype. Int. J. Cancer 78:699.
9. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Liénard, D., Cerottini, J.-C. and Cerundolo, V. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J. Exp. Med. 188:1641.
10. Cohen, E. P. and Kim, T. S. 1994. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:419
11. Cromme, F. V., Airey, J., Heemels, M.-T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J. L. M. and Walboomers, J. M. M. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335.
12. Ye, X., McCarrick, J., Jewett, L. and Knowles, B. B. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl Acad. Sci. USA 91:3916.
13. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Viliar, J. J., Lopez-Botet, M., Duggan-Keen, M. and Stern, P. L. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18:89.
14. Onrust, S. V, Hartl, P. M., Rosen, S. D. and Hanahan, D. 1996. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97:54.
15. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 24:1966.
16. Gervois, N., Guilloux, Y., Diez, E. and Jotereau, F. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183:2403.
17. Kersh, G. J. and Allen, P. M. 1996. Essential flexibility in the T-cell recognition of antigen. Nature 380:495.
18. Dressel, A., Chin, J. L., Sette, A., Gausling, R., Hollsberg, P. and Hafler, D. A. 1997. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol. 159:4943.
19. Vergelli, M., Hemmer, B., Kalbus, M., Vogt, A. B., Ling, N., Conlon, P., Coligan, J. E., McFarland, H. and Martin, R. 1997. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J. Immunol. 158:3746.
20. Nicholson, L. B., Waldner, H., Carrizosa, A. M., Sette, A., Collins, M. and Kuchroo, V. K. 1998. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc. Natl Acad. Sci. USA 95:264.
21. Valitutti, S., Muller, S., Dessing, M. and Lanzavecchia, A. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1917.
22. Bachmann, M. F., Oxenius, A., Speiser, D. E., Mariathasan, S., Hengartner, H., Zinkernagel, R. M. and Ohashi, P. S. 1997. Peptide induced TCR-down regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. Eur. J. Immunol. 27:2195.
23. Valmori, D., Fonteneau, J. F., Marañón Lizana, C., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, C. V., Jotereau F., Cerottini, J.-C. and Romero, P. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs J. Immunol. 160:1750.
24. (Black star)0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 161:6956.
25. (Black star)0201/Kb transgenic mice. J. Immunol. 162:3566.
26. Salter, R. D., Howell, D. N. and Cresswell, P. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235.
27. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., Cerundolo, V., Hurley, A., Markowicz, M., Ho, D. D., Nixon, D. F. and McMichael, A. J. 1998. Quantilation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.
28. Valitutti, S., Dessing, M., Aktories, K., Gallati, H. and Lanzavecchia, A. 1995. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 181:577.
29. Jung, T., Schauer, U., Heusser, C., Neumann, C. and Rieger, C. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159:197.
30. (Black star)0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
31. Bachmann, M. F., Sebzda, E., Kündig, T. M., Shahinian, A., Speiser, D, E., Mak, T. W. and Ohashi, P. S. 1996. T cell responses are governed by avidity and co-stimulatory thresholds. Eur. J. Immunol. 26:2017.
32. Fonteneau, J. F., Le Dréan, E., Le Guiner, S., Gervois, N., Diez, E. and Jotereau, F. 1997. Heterogeneity of biologic responses of melanoma-specific CTL. J. Immunol. 159:2831.
33. Speiser, D. E., Kyburz, D., Stübi, U., Hengartner, H. and Zinkernagel, R. M. 1992 Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities: low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide coated target cells but not for in vivo protection. J. Immunol. 149:972.
34. Nossal, G. J. V. 1994. Negative selection of lymphocytes. Cell 76:229.
35. von Boehmer, H. 1994. Positive selection of lymphocytes. Cell 76:219.
36. Falk, K., Rötzschke, O., Stevanovic, S. Jung, G. and Rammensee, H. G. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
37. Rammensee, H. G., Friede, T. and Stevanovic, S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
38. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M. and Sette, A. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
39. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397.